Controlled release formulation of ranitidine-containing montmorillonite and Eudragit E-100.
The objective of this work was to illustrate the suitability of montmorillonite (MMT) as a drug delivery carrier, by developing a new clay-drug composite of ranitidine hydrochloride (RT) intercalated in MMT. The MMT-RT composite was prepared by ion-exchange process. X-ray diffraction and Fourier transform infrared spectra were employed to confirm the intercalation of RT in the MMT interlayers. The prepared MMT-RT hybrid was coated with cationic polymer Eudragit E-100 by oil-in-water solvent evaporation method. The release processes of RT from MMT-RT and MMT-RT/Eudragit E-100 were monitored under in vitro condition in the gastric fluid. X-ray diffraction and Fourier transform infrared spectra analysis indicated the intercalation of RT molecules within the clay lattice. The in vitro release studies showed that MMT-RT released RT in a controlled manner. In the case of MMT-RT/Eudragit E-100, both the release rate and the release percentages noticeably increased in the presence of Eudragit E-100, because of its effective exchange with intercalated RT molecules. The release kinetics followed parabolic diffusion mechanism. MMT has great potential as a drug delivery carrier with various scenarios. The dosage of the MMT-RT/Eudragit E-100 can be in the tablet form. The hybrid material and polymer-coated hybrids are microparticles.